Development of a Live Topical Microbicide for Women
女性外用活杀微生物剂的开发
基本信息
- 批准号:8145510
- 负责人:
- 金额:$ 42.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-29 至 2011-09-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAnimalsAntibiotic ResistanceAntibioticsBacteriaBacterial VaginosisBiological MarkersBiological ProductsBiomedical EngineeringCell LineCervicalChinese PeopleChromosomesCoculture TechniquesCollectionConsultationsCyanovirin-NDevelopmentDoseDrug EvaluationDrug FormulationsEpidemiologic StudiesEpithelial CellsEpitheliumEvaluation ResearchFemaleGenerationsGeneticGenetically Modified OrganismsGenital systemGenome StabilityHIVHIV Entry InhibitorsHIV-1HeterosexualsHumanHuman VolunteersHydrogenHydrogen PeroxideImmuneIn SituInfectionInvestigational DrugsInvestigational New Drug ApplicationLactobacillusLeadLifeLocal MicrobicidesMacaca mulattaModelingOpportunistic InfectionsOrganismPharmacologic SubstancePhasePhase II Clinical TrialsProteinsRecombinantsRecurrenceRiskSafetySeminal PlasmaSexually Transmitted DiseasesTherapeuticTransferenceUnited States Dept. of Health and Human ServicesUrinary tract infectionVaginaViralWomanWorkbasedesignimmunogenicityimmunotoxicitymanufacturing processmicrobicidenonhuman primatenovelpathogenpre-clinicalpreclinical safetypreclinical studypreventself-renewalsimian human immunodeficiency virustransmission processvaginal lactobacillivolunteer
项目摘要
DESCRIPTION (provided by applicant): Osel, Inc. is a biopharmaceutical company specializing in the development of bacterial therapeutics. The company's lead product, LACTIN-V, is a naturally occurring human vaginal isolate of Lactobacillus crispatus presently undergoing phase II clinical trials to examine its safety and efficacy in preventing recurrent urinary tract infections and bacterial vaginosis (BV). Both of these infections are characterized by a depletion of hydrogen peroxide (H2O2)-producing lactobacilli that normally protect the vagina from infection by opportunistic pathogens. Epidemiological studies also suggest that loss of vaginal lactobacilli is associated with an increased risk of heterosexual HIV-1 transmission and other sexually transmitted infections. LACTIN-V represents an ecological approach to prevent vaginal infections by re-establishing the protective vaginal flora with a colonizing, H2O2-producing Lactobacillus strain.
A second-generation Lactobacillus product, and the topic of this proposal, is a human vaginal isolate of H2O2-producing L. jensenii that has been genetically enhanced to constitutively secrete high levels of the potent HIV entry inhibitor cyanovirin-N (CV-N). This live, self-renewing microbicide may afford an efficacious, yet inexpensive means to deliver a protein-based microbicide and addresses the urgent need for female-controlled approaches to block heterosexual transmission of HIV-1.
In this R21 proposal, we will select a microbicide development candidate from a collection of bioengineered strains that contain optimized CV-N expression cassettes stably integrated into the L. jensenii chromosome. We will employ a Chinese rhesus macaque (Macaca mulatta) model that affords persistent vaginal colonization of L. jensenii to conduct preclinical safety and efficacy studies, including in situ CV-N expression, immunotoxicity, and efficacy against mucosal viral transmission. Furthermore, we propose to evaluate potential regulatory issues concerning the pharmaceutical development of a genetically modified organism, and to optimize the formulation and manufacturing processes for this product. Following a pre-IND consultation with the FDA, we will file an exploratory IND application and then initiate two exploratory phase 0 studies in the R33 phase of the proposal to assess the effects of the recombinant L. jensenii strain on safety, tolerability, innate genital tract immune factors, vaginal colonization, and clearance of the organism after antibiotic administration in healthy female volunteers.
描述(申请人提供):OSEL,Inc.是一家专门从事细菌疗法开发的生物制药公司。该公司的主导产品LACTIN-V是一种自然产生的人类阴道乳杆菌分离物,目前正在进行第二阶段临床试验,以检验其在预防复发尿路感染和细菌性阴道病(BV)方面的安全性和有效性。这两种感染的特征都是产生过氧化氢(H2O2)的乳酸菌枯竭,这种乳酸菌通常可以保护阴道免受机会性病原体的感染。流行病学研究还表明,阴道乳酸菌的丧失与异性传播HIV-1和其他性传播感染的风险增加有关。LACTIN-V代表了一种预防阴道感染的生态方法,方法是用一种定植的、产生过氧化氢的乳杆菌菌株重建保护阴道的菌群。
第二代乳杆菌产品,也是这项提案的主题,是一种产生过氧化氢的詹森氏乳杆菌的人类阴道分离株,这种乳杆菌已经经过基因增强,能够结构性地分泌高水平的有效艾滋病毒进入抑制剂氰韦林-N(CV-N)。这种活的、自我更新的杀微生物剂可能提供一种有效但廉价的方法来提供基于蛋白质的杀微生物剂,并解决女性控制的方法的迫切需要,以阻止艾滋病毒-1的异性传播。
在这份R21提案中,我们将从一组生物工程菌株中选择一种杀菌剂开发候选菌株,这些生物工程菌株含有稳定整合到简氏乳杆菌染色体上的优化的CV-N表达盒。我们将使用中国恒河猴(Macaca Mulatta)模型进行临床前安全性和有效性研究,包括原位CV-N表达、免疫毒性和对抗粘膜病毒传播的有效性。此外,我们建议评估与转基因生物的药物开发有关的潜在监管问题,并优化该产品的配方和制造工艺。在与FDA进行IND前咨询后,我们将提交IND的探索性申请,然后在提案的R33阶段启动两项探索性的0期研究,以评估重组L.jensenii菌株对健康女性志愿者使用抗生素后的安全性、耐受性、先天性生殖道免疫因子、阴道定植和机体清除的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laurel A. Lagenaur其他文献
Laurel A. Lagenaur的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laurel A. Lagenaur', 18)}}的其他基金
MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial
MucoCept-CVN,一种基因增强的阴道乳杆菌菌株,用于预防女性感染艾滋病毒:首次人体临床试验的配方最终确定
- 批准号:
9905651 - 财政年份:2020
- 资助金额:
$ 42.57万 - 项目类别:
MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial
MucoCept-CVN,一种基因增强的阴道乳杆菌菌株,用于预防女性感染艾滋病毒:首次人体临床试验的配方最终确定
- 批准号:
10223989 - 财政年份:2020
- 资助金额:
$ 42.57万 - 项目类别:
Development of a rapid point of care diagnostic,to monitor MucoCept-CVN, an HIV-targeted biotherapy,
开发快速护理诊断,以监测 MucoCept-CVN(一种针对 HIV 的生物疗法)
- 批准号:
9137087 - 财政年份:2016
- 资助金额:
$ 42.57万 - 项目类别:
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bioengineered to secrete broadly neutralizing domain antibodies
使用经生物工程改造可分泌广泛中和域抗体的共生阴道乳杆菌提供针对 HIV 的被动免疫
- 批准号:
8658658 - 财政年份:2012
- 资助金额:
$ 42.57万 - 项目类别:
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bi
使用共生阴道双乳杆菌提供针对 HIV 的被动免疫
- 批准号:
8329194 - 财政年份:2012
- 资助金额:
$ 42.57万 - 项目类别:
Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bioengineered to secrete broadly neutralizing domain antibodies
使用经生物工程改造可分泌广泛中和域抗体的共生阴道乳杆菌提供针对 HIV 的被动免疫
- 批准号:
8906724 - 财政年份:2012
- 资助金额:
$ 42.57万 - 项目类别:
Development of Bacterial Therapeutics Targeting Bacterial Vaginosis-Associated Bi
针对细菌性阴道病相关双歧杆菌的细菌疗法的开发
- 批准号:
7925857 - 财政年份:2010
- 资助金额:
$ 42.57万 - 项目类别:
Development of a Live Combinational Microbicide for Women
女性用活性复合杀微生物剂的开发
- 批准号:
7786986 - 财政年份:2009
- 资助金额:
$ 42.57万 - 项目类别:
Development of a Live Topical Microbicide for Women
女性外用活杀微生物剂的开发
- 批准号:
7937801 - 财政年份:2007
- 资助金额:
$ 42.57万 - 项目类别:
Development of a Live Topical Microbicide for Women
女性外用活杀微生物剂的开发
- 批准号:
8126267 - 财政年份:2007
- 资助金额:
$ 42.57万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 42.57万 - 项目类别:
Fellowship Programs